CLONING GENES WITH AN EPISOMAL VECTOR

用附加载体克隆基因

• 批准号: 3198870
• 负责人: ROBERT T SCHIMKE
• 金额: $ 24.06万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-05-01 至 1994-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3198870
• 关键词: R factors; ataxia telangiectasia; biological transport; complementary DNA; cytogenetics; flow cytometry; gene complementation; gene duplication; gene mutation; genetic manipulation; genetic techniques; genetic transcription; genome; human genetic material tag; human tissue; methotrexate; molecular cloning; molecular genetics; nucleic acid sequence; transfection; transposon /insertion element

DESCRIPTION: (Adapted from Investigator's Abstract) This research proposal involves the development of a mammalian vector system that replicates episomally and the development of new methods for the insertion of cDNA libraries into it. Because the vector remains episomal, it can be recovered rapidly and readily. In this respect it differs from previously described vectors that integrate rapidly into the host (human) cell genome, and hence, cannot be recovered readily. This system can be used to complement defective functions of human cells where the gene is unknown and where a selection can be imparted. Part of the proposal is to continue development of the vector system. Additionally the investigators propose to identify human genes which have not previously been identified: 1) Ataxia telangiectasia, specifically complementation group D; 2) gene(s) coding for methotrexate transport, genes which in a defective form result in a common form of methotrexate resistance in cancer cells.

描述：（根据调查员的摘要进行了改编）该研究建议 涉及复制的哺乳动物矢量系统的开发 偶发和开发插入cDNA的新方法 库中的图书馆。 因为矢量仍然是偶发的，所以可以是 迅速而轻松地恢复。 在这方面，它与以前不同 描述了迅速整合到宿主（人）细胞基因组的载体， 因此，不能轻易恢复。 该系统可用于 补体人细胞的缺陷功能，其中基因未知和 可以进行选择的地方。 提案的一部分是继续 向量系统的开发。 此外，调查人员提出了 确定以前尚未鉴定的人类基因：1） 催化性共济失调，特别是互补组D； 2）基因 编码甲氨蝶呤转运，以缺陷形式的基因 以癌细胞中甲氨蝶呤耐药性的共同形式。